RLMD News and Press, Relmada Therapeutics Inc. From 03/16/22

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 23, 2022 PR Newswire CORAL GABLES, Fla. , March 16, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage ...

Relmada Therapeutics to Participate in Fireside Chats at Two Upcoming Healthcare Events PR Newswire CORAL GABLES, Fla. , March 10, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the c...

Palm Beach, FL –– February 24, 2022  – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept pace, precipitating a crisis in psychiatric me...

Gainers: Revelation Biosciences REVB +29%. Mainz Biomed MYNZ +9%. Relmada Therapeutics (NASDAQ:RLMD) +9%. Panbela Therapeutics (NASDAQ:PBLA) +7%. Pyxis Oncology (NASDAQ:PYXS) +4%. Losers: Kodiak Sciences KOD -78%. Ocugen OCGN -20%. R...

The development stage biotech company, Relmada Therapeutics (NASDAQ:RLMD) announced on Wednesday the topline results from the human abuse potential (HAP) study for its lead candidate REL-1017, currently in Phase 3 development for major depressive disorder (MDD). The Phase 1 study was designed...

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential - All doses of REL-1017, including the maximum tolerated dose, demonstrated a statistically significant difference in abuse potential vs. ketamine (p-values <0.05) ...

Relmada Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference PR Newswire CORAL GABLES, Fla. , Feb. 10, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases o...

Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry - Manuscript further details findings from study assessing REL-1017 as adjunctive treatment for MDD - Primary endpoint results included rapid, significant, and ...

Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Sichenzia Ross Ference LLP today announced that it represented Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system, in an upsized underwritten public offering. The offerin...